COMPANY NEWS


Granules India Ltd
BSE Code 532482 ISIN Demat INE101D01020 Book Value (₹) 118.38 NSE Symbol GRANULES Div & Yield % 0.35 Market Cap ( Cr.) 10,283.70 P/E * 22.17 EPS * 19.14 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Granules India receives USFDA approval for Losartan Potassium and Hydrochlorothiazide Tablets Back
(30 Sep 2023)
Granules India announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Hyzaar Tablets of Organon LLC.

Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension to lower blood pressure and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Granules now have a total of 60 ANDA approvals from US FDA (58 Final approvals and 2 tentative approvals)